Posters

One year follow-up of 26 patients in a multicenter study with the Femtis lens (Oculentis, The Netherlands) regarding safety, efficiency, and stability in the capsular bag

Poster Details

First Author: D.Holland GERMANY

Co Author(s):    F. Ruefer   I. Matthaie   M. Poelz              

Abstract Details

Purpose:

To investigate the safety and efficiency of a the Femtis lens in FLACS in a one year follow up in a prospective study.

Setting:

nordBlick Augenklinik Bellevue, Kiel, Germany

Methods:

Patients were operated for cataract surgery with the LENSAR laser system by the same surgeon after inclusion in the study. Inclusion criteria where cataract eyes with no further pathology and corneal astigmatism below 0,75 dpt. Follow up were at day one and six weeks, six months and one year after surgery. Intraoperative adverse events as well as the surgeon´s appreciation concerning the implantation were documented. Visual acuity, rotation stability, decentration and PCO were examined by every follow up.

Results:

No adverse events occured intraoperatively nor in the follow up. Spherical equivalent developed from 0.5dpt to 0.25 dpt. UCDVA changed from preoperative 0.5 logMar to 0.03logMar and CDVA from 0.2logMar to -0.15logMar at 12 month postoperative. PCO scale showed no significant PCO after 12 month and no yag laser capsulotomy was performed.. Rotation stability was below one degree. Decentration was 0.02 mm after one year. Intraocular pressure was normal in all eyes within the follow up. The investigative questionaire regarding the intraoperative performance of the lens showed 1.1 in average (school notes from 1/ best - 5/worst).

Conclusions:

The Femtis lens is a safe new IOL design for FLACS. The intraoperative behaviour is good and the implantation easy to perform. The follow ups showed stable refractive results and good UCDVA. Regarding decentration and rotation stability, the Femtis lens is showing better results compared to standard monofokal IOL. To judge the development of PCO, a longer follow up is necessary.

Financial Disclosure:

gains financially from competing product or procedure, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented